A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin {alpha}

JOURNAL OF INTENSIVE CARE MEDICINE
VOL 24; NUMB 1; 2009
ISSN 0885-0666

http://zetoc.mimas.ac.uk/wzgw?db=etoc&terms=RN245058480&field=zid

Date: 2009
Objectives:
To study the effect of immunomodulatory therapy with ulinastatin plus thymosin alpha( 1) on septic patients. Method: A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo. Acute Physiology and Chronic Health Evaluation II scores, clinical data, lymphocyte subsets, immunological indexes, and coagulation parameters were determined before admission and on the 3rd, 8th, and 28th day after admission to the Intensive Care Unit. Results: The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic...